The NCI preclinical screen of biological response modifiers
Related Experiment Videos
Abstract:
The development of successful approaches to immunotherapy is dependent upon proper consideration of the pathobiology of metastasis and the establishment of a better scientific understanding of the principles of biological response modification. The studies we have undertaken are aimed at the rational development of a preclinical data base to help provide this understanding. Ultimately, these studies will be correlated with clinical trials to assess the predictive value of the preclinical screen. We anticipate that the testing of biological response modifiers (BRMs) in a controlled but evolving system will help eliminate arbitrary decisions on the preparations and use of a given BRM and ultimately will contribute to the development of novel approaches for the treatment of disseminated cancer. Immunotherapy alone or in combination with other therapeutic modalities is an area of rapid evolution with tremendous potential as an adjuvant therapy of disseminated cancer.
Insights
This study focuses on developing a preclinical database for biological response modifiers (BRMs) to advance cancer immunotherapy. By understanding metastasis and BRM principles, researchers aim to improve treatment strategies for disseminated cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Metastasis
Background:
- Successful immunotherapy requires understanding cancer metastasis and biological response modification.
- Current approaches may benefit from a more rational, data-driven development process.
Purpose of the Study:
- To develop a preclinical database for biological response modifiers (BRMs).
- To enhance the scientific understanding of biological response modification principles.
- To correlate preclinical findings with clinical trials for predictive value.
Main Methods:
- Undertaking studies to build a rational preclinical database.
- Testing biological response modifiers (BRMs) in a controlled, evolving system.
- Correlating preclinical data with clinical trials.
Main Results:
- Establishing a scientific understanding of biological response modification.
- Developing a preclinical database to guide BRM selection and use.
- Identifying potential for novel immunotherapy approaches.
Conclusions:
- A rational approach to BRM development can reduce arbitrary decisions.
- Immunotherapy holds significant potential as adjuvant therapy for disseminated cancer.
- Further research aims to refine immunotherapy strategies through preclinical and clinical correlation.